Insulin infusion set: The Achilles heel of continuous subcutaneous insulin infusion

Journal of Diabetes Science and Technology

Volumn 6, Issue 4, 2012, Pages 954-964

  Heinemann, Lutz ^a   Krinelke, Lars ^b  

^a Science and Co   (Germany)

^b Roche Diabetes Care AG   (Switzerland)

Author keywords

Infusion set; Insulin pumps; Insulin therapy

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN LISPRO; ANTIDIABETIC AGENT;

ABSCESS; BLISTER; CANNULA; CONTACT DERMATITIS; DERMATITIS; DISINFECTION; DRUG ABSORPTION; ERYTHEMA; HUMAN; INJECTION SITE INFECTION; INSULIN INFUSION; INSULIN PUMP; INSULIN TREATMENT; METABOLIC REGULATION; NEEDLE; PAIN; PRURITUS; REVIEW; SCAR; SKIN DISEASE; TOXIC SHOCK SYNDROME; ACHILLES TENDON; DIABETES MELLITUS; EVALUATION; HEEL; LITERATURE; METHODOLOGY; PATIENT EDUCATION; STANDARD; SUBCUTANEOUS DRUG ADMINISTRATION;

ACHILLES TENDON; DIABETES MELLITUS; DISINFECTION; HEEL; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MYTHOLOGY; NEEDLES; PATIENT EDUCATION AS TOPIC;

EID: 84869080901     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600429     Document Type: Review

References (67)

1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26(4):1079-87.
2. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care. 2008;31 Suppl 2:S140-5.
3. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, Waugh N. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(11):iii-iv, xi-xvi, 1-181.
4. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, Siebenhofer A. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51(6):941-51. Epub 2008 Mar 20.
5. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765-74.
6. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F; European Society for Paediatric Endocrinology; Lawson Wilkins Pediatric Endocrine Society; International Society for Pediatric and Adolescent Diabetes; American Diabetes Association; European Association for the Study of Diabetes. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30(6):1653-62.Epub 2007 Mar 19.
7. Heinemann L. Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements? J Diabetes Sci Technol. 2009;3(6):1490-500.
8. Zisser HC. The OmniPod Insulin Management System: the latest innovation in insulin pump therapy. Diabetes Ther. 2010;1(1):10-24. Epub 2010 Sep 13.
9. Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26(6):1519-30.
10. Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, Letondeur C, Sauvanet JP, Tubiana-Rufi N, Strauss K; Scientific Advisory Board for the Third Injection Technique Workshop. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36 Suppl 2:S3-18.
11. Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, Letondeur C, Sauvanet JP, Tubiana-Rufi N, Strauss K. The Third Injection Technique Workshop in Athens (TITAN). Diabetes Metab. 2010;36 Suppl 2:S19-29.
12. Scheiner G, Sobel RJ, Smith DE, Pick AJ, Kruger D, King J, Green K. Insulin pump therapy: guidelines for successful outcomes. Diabetes Educ. 2009;35 Suppl 2:29S-41S.
13. Heinemann L, Steiner S. Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same? J Diabetes Sci Technol. 2011;5(5):1027-9.
14. Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5(2):77-91.
15. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366-76.
16. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92(1):59-61.
17. Zehrer C, Hansen R, Bantle J. Reducing blood glucose variability by use of abdominal insulin injection sites. Diabetes Educ. 1990;16(6):474-7.
18. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16(12):1592-7.
19. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-6.
20. Vora JP, Burch A, Peters JR, Owens DR. Absorption of radiolabelled soluble insulin in type 1 (insulin-dependent) diabetes: influence of subcutaneous blood flow and anthropometry. Diabet Med. 1993;10(8):736-43.
21. Frid A, Linde B. Intraregional differences in the absorption of unmodified insulin from the abdominal wall. Diabet Med. 1992;9(3):236-9.
22. Frid A, Linde B. Clinically important differences in insulin absorption from abdomen in IDDM. Diabetes Res Clin Pract. 1993;21(2-3):137-41.
23. Ter Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH, Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996;19(12):1437-40.
24. Bargero G, Capra Marzani M, Fasano M, Guazzo G, Minoglio A, Rosso A. [Relations between the site of insulin absorption and hypoglycemia in insulin-dependent diabetes during physical exertion]. Minerva Med. 1986;77(27):1285-8.
25. Koivisto VA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. N Engl J Med. 1978;298(2):79-83.
26. Van Faassen I, Razenberg PP, Simoons-Smit AM, van der Veen EA. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy. Diabetes Care. 1989;12(2):153-5.
27. Liebner T, Holl R, Heidtmann B, Lilienthal B, Molz K, Hungele A, Bergheim I, Gialeli G. Insulinpumpenkatheter: Komplikationen im Kindes- und Jugendalter. Diabetologie und Stoffwechsel. 2011;6:S52.
28. Hammond P, Liebl A, Grunder S. International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life. Prim Care Diabetes. 2007;1(3):143-6.
29. Nguyen TV, Burnett JW. Local skin reaction caused by the plastic catheter tubing of the continuous subcutaneous insulin infusion system. Cutis. 1988;41(5):355-6.
30. Levandoski LA, White NH, Santiago JV. Localized skin reactions to insulin: insulin lipodystrophies and skin reactions to pumped subcutaneous insulin therapy. Diabetes Care. 1982;5 Suppl 1:6-10.
31. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4(10):661-7.
32. Clausen TS, Kaastrup P, Stallknecht B. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol Ther. 11(9):575-80.
33. Højbjerre L, Skov-Jensen C, Kaastrup P, Pedersen PE, Stallknecht B. Effect of steel and teflon infusion catheters on subcutaneous adipose tissue blood flow and infusion counter pressure in humans. Diabetes Technol Ther. 2009;11(5):301-6.
34. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2008;2(3):450-5.
35. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2005;7(1):142-50.
36. Schmid V, Hohberg C, Borchert M, Forst T, Pfützner A. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol. 2010;4(4):976-82.
37. Johansson UB, Adamson U, Lins PE, Wredling R. Patient management of long-term continuous subcutaneous insulin infusion. J Adv Nurs. 2005;51(2):112-8.
38. Schifferdecker E, Schmidt K, Boehm BO, Schatz H. Long-term compliance of intensified insulin therapy. Diabetes Res Clin Pract. 1994;23(1):17-23.
39. Wood JR, Moreland EC, Volkening LK, Svoren BM, Butler DA, Laffel LM. Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care. 2006;29(11):2355-60.
40. De Vries L, Grushka Y, Lebenthal Y, Shalitin S, Phillip M. Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes. Pediatr Diabetes. 2011;12(5):506-12. Epub 2010 Aug 15.
41. Mecklenburg RS, Benson EA, Benson JW Jr, Fredlund PN, Guinn T, Metz RJ, Nielsen RL, Sanner CA. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA. 1984;252(23):3265-9.
42. Van Faassen I, Razenberg PP, Simoons-Smit AM, van der Veen EA. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy. Diabetes Care. 1989;12(2):153-5.
43. Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care. 1988;11(1):46-51.
44. Chantelau E, Spraul M, Mühlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989;32(7):421-6.
45. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri E, Lora L, Guarneri G, Mongillo A, Gennaro R, Miola M, Moretti M, Confortin L, Beltramello GP, Pais M, Baritussio A, Casiglia E, Tiengo A. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med. 2002;19(8):628-34.
46. Teutsch SM, Herman WH, Dwyer DM, Lane JM. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med. 1984;310(6):361-8.
47. Centers for Disease Control (CDC). Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump-Idaho. MMWR Morb Mortal Wkly Rep 1983;32(31):404-6, 412.
48. Nowakowska M, Jarosz-Chobot P, Polańska J, Machnica Ł. Bacterial strains colonizing subcutaneous catheters of personal insulin pumps. Pol J Microbiol. 2007;56(4):239-43.
49. Chantelau E, Lange G, Sonnenberg GE, Berger M. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment. Diabetes Care. 1987;10(4):478-82.
50. Chantelau E, Lange G, Gasthaus M, Boxberger M, Berger M. Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy. Diabetes Care. 1987;10(3):348-51.
51. Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152(5):622-8. Epub 2008 Jan 22.
52. Schober E, Rami B. Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool-age and school-age children. Pediatr Diabetes. 2009;10(3):198-201. Epub 2008 Nov 3.
53. Murdolo G, Herder C, Wang Z, Rose B, Schmelz M, Jansson PA. In situ profiling of adipokines in subcutaneous microdialysates from lean and obese individuals. Am J Physiol Endocrinol Metab. 2008;295(5):E1095-105. Epub 2008 Sep 9.
54. Pachler C, Ikeoka D, Plank J, Weinhandl H, Suppan M, Mader JK, Bodenlenz M, Regittnig W, Mangge H, Pieber TR, Ellmerer M. Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans. Am J Physiol Endocrinol Metab. 2007;293(3):E690-6. Epub 2007 Jun 19.
55. Wisniewski N, Rajamand N, Adamsson U, Lins PE, Reichert WM, Klitzman B, Ungerstedt U. Analyte flux through chronically implanted subcutaneous polyamide membranes differs in humans and rats. Am J Physiol Endocrinol Metab. 2002;282(6):E1316-23.
56. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983;24(5):326-9.
57. Hirsch IB, Farkas-Hirsch R, McGill JB. Catheter obstruction with continuous subcutaneous insulin infusion. Effect of insulin concentration. Diabetes Care. 1992;15(4):593-4.
58. Wiefels K, Hübinger A, Dannehl K, Gries FA. Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Horm Metab Res. 1995;27(9):421-4.
59. Liu D, Moberg E, Wredling R, Lins PE, Adamson U. Insulin absorption is faster when keeping the infusion site in use for three days during continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 1991;12(1):19-24.
60. Olsson PO, Arnqvist H, Asplund J. No pharmacokinetic effect of retaining the infusion site up to four days during continuous subcutaneous insulin infusion therapy. Diabet Med. 1993;10(5):477-80.
61. Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32(2):240-4. Epub 2008 Nov 18.
62. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001;24(1):69-72.
63. Thethi TK, Rao A, Kawji H, Mallik T, Yau CL, Christians U, Fonseca V. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications. 2010;24(2):73-8. Epub 2009 Apr 23.
64. Mecklenburg RS, Guinn TS, Sannar CA, Blumenstein BA. Malfunction of continuous subcutaneous insulin infusion systems: a one-year prospective study of 127 patients. Diabetes Care. 1986;9(4):351-5.
65. Pickup JC, Sherwin RS, Tamborlane WV, Rizza RA, Service FJ. Conference on insulin pump therapy in diabetes. Multicenter study of effect on microvascular disease. The pump life. Patient responses and clinical and technological problems. Diabetes. 1985;34 Suppl 3:37-41.
66. Peden NR, Braaten JT, McKendry JB. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes Care. 1984;7(1):1-5.
67. Renard E, Guerci B, Leguerrier AM, Boizel R; Accu-Chek FlexLink Study Group. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther. 2010;12(10):769-73.